Loncastuximab tesirine

• UNSPSC Description:

  Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma[1][2].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); Apoptosis

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/loncastuximab-tesirine.html

• Purity:

  99.37

• Solubility:

  10 mM in DMSO

• Smiles:

  [Loncastuximab tesirine]

• Molecular Weight:

  147000 (average)

• References & Citations:

  [1]Nikoleta Sachini, et al. Combination of Loncastuximab Tesirine and Polatuzumab Vedotin Shows Increased Anti-Tumor Activity in Pre-Clinical Models of Non-Hodgkin Lymphoma. Blood. 2021.|[2]Zammarchi F, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  -80°C, protect from light

• Clinical Information:

  Launched

• CAS Number:

  1879918-31-6